IDXX
NASDAQ · Health Care
Idexx Laboratories Inc
$575.72
+5.51 (+0.97%)
Performance
1D
—
1W
—
1M
—
3M
-16.38%
6M
-8.70%
1Y
+37.83%
YTD
-14.07%
Open$581.10
Previous Close$570.21
Day High$581.63
Day Low$562.35
52W High$769.98
52W Low$356.14
Volume—
Avg Volume495.2K
Market Cap50.24B
P/E Ratio47.42
EPS$13.08
SectorHealth Care
Technical Indicators
Full analysis →
SMA 50
$681.23
Below
SMA 200
$623.83
Below
RSI (14)
32.3
Neutral
Trend
Golden Cross
Bullish
Analyst Ratings
Buy
22 analysts
Price Target
-71.3% upside
Current
$575.72
$575.72
Target
$165.33
$165.33
$97.53
$165.33 avg
$206.49
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 4.20B | 3.87B | 10.62B |
| Net Income | 1.03B | 858.09M | 1.10B |
| Profit Margin | 24.6% | 23.4% | 10.3% |
| EBITDA | 1.33B | 1.16B | 2.07B |
| Free Cash Flow | — | — | 651.24M |
| Rev Growth | +8.5% | +8.5% | +24.1% |
| Debt/Equity | 0.53 | 0.53 | 0.08 |
About Idexx Laboratories Inc
IDEXX Laboratories, Inc. is the world's leading provider of diagnostic products and services for companion animal veterinary medicine, headquartered in Westbrook, Maine. The company develops and distributes point-of-care veterinary diagnostic instruments and consumables, reference laboratory diagnostic and consulting services, and practice management software for the veterinary market. IDEXX also offers diagnostic products for livestock and poultry, water quality testing, and dairy testing applications. Its companion animal diagnostics franchise holds a commanding global market position, supported by a large installed base of proprietary instruments with high recurring consumable usage.
Health Care Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| UNH | UnitedHealth Group Inc | $270.55 | -0.64% | 21.7 | 261.12B |
| ABT | Abbott Laboratories | $104.83 | +0.74% | 28.3 | 184.68B |
| ISRG | Intuitive Surgical Inc | $469.98 | -0.41% | 59.8 | 170.78B |
| SYK | Stryker Corp | $327.65 | -0.26% | 39.5 | 128.28B |
| MDT | Medtronic Plc | $87.89 | +1.51% | 24.1 | 111.30B |
| MCK | Mckesson Corp | $879.75 | -0.25% | 25.1 | 109.03B |
IDXX Frequently Asked Questions
What does IDEXX Laboratories do?
IDEXX makes the diagnostic instruments, test kits, and software platforms that veterinary clinics use to analyze blood, urine, and other patient samples from companion animals. Its in-clinic analyzers — the Catalyst chemistry analyzer and ProCyte hematology system — sit in thousands of veterinary practices worldwide, processing routine diagnostics that practitioners use daily. A separate reference laboratory network handles more complex testing sent in from clinics. The company also operates a veterinary software business that manages practice workflows, creating additional switching costs on top of instrument placement.
Is IDXX stock a good investment?
IDEXX has built one of the most defensible business models in the diagnostics industry by placing analyzers in clinics and then generating recurring, high-margin revenue from the test consumables those instruments require — a classic razor-and-blades model. The installed base compounds over time as new clinics are added and existing customers run more tests. Profitability metrics are exceptional, with margins that reflect pricing power and operational leverage. The stock historically trades at a significant premium, and any growth slowdown from pet population maturity or veterinary visit rate stagnation could pressure that premium.
Who are IDEXX Laboratories' main competitors?
Heska Corporation (acquired by Mars, owner of Banfield Pet Hospitals) competes with IDEXX in in-clinic diagnostic analyzers and has benefited from deep ties to veterinary hospital chains. Zoetis has diagnostic products and competes at the periphery, but is primarily focused on medicines. Antech Diagnostics, also owned by Mars, operates a competing reference laboratory network. Neogen competes in food safety and some animal testing adjacent markets. Randox and Biovetia compete internationally in veterinary diagnostics.
What makes IDXX stock unique?
IDEXX has achieved a level of market penetration in companion animal diagnostics that most medical device companies never reach in human healthcare. The combination of an extensive installed base of analyzers, a proprietary consumable supply model, and practice management software creates three separate switching cost mechanisms in the same customer relationship. This means veterinary practices that adopt IDEXX rarely leave. The secular growth in pet ownership, pet insurance adoption, and rising spending per pet visit provide multi-year revenue tailwinds without requiring constant product reinvention.
How much does IDXX stock cost right now?
IDXX last closed at $575.72, up 0.97% in the most recent trading session. Over the past 52 weeks, the stock has traded between a low of $356.14 and a high of $769.98. The current price represents 53% of its 52-week range, which helps investors gauge where the stock sits relative to its recent trading history.
What is the analyst consensus for IDXX?
Among 22 analysts covering IDXX, the consensus rating is Buy — 16 rate it a buy, 6 hold, and 0 sell. The average price target sits at $165.33, implying 71% downside from the current price. Keep in mind that analyst targets reflect 12-month expectations and can shift quickly after earnings reports or major company events.
Does Idexx Laboratories Inc make money?
Idexx Laboratories Inc generated $4.20B in revenue during fiscal year 2026, with $1.03B reaching the bottom line as net income. The net profit margin of 24.6% is strong by most industry standards.
Is IDXX stock expensive based on earnings?
IDXX trades at a P/E ratio of 47.42 on trailing earnings of $13.08 per share. That's above the S&P 500 historical average, suggesting the market expects above-average earnings growth ahead. Comparing this multiple against Health Care sector peers gives better context than the broad market alone, since P/E norms vary significantly across industries.
Is IDXX stock going up or down?
Performance varies across timeframes, reflecting shifting market conditions. Returns by timeframe: -16.38% (3M), -8.70% (6M), +37.83% (1Y), -14.07% (YTD). Comparing these figures against the S&P 500 and sector benchmarks helps determine whether IDXX is outperforming or lagging the broader market.